These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. McGovern AP; Jones S; van Vlymen J; Saggar AK; Sandford R; de Lusignan S BMC Nephrol; 2014 Nov; 15():182. PubMed ID: 25412767 [TBL] [Abstract][Full Text] [Related]
5. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552 [TBL] [Abstract][Full Text] [Related]
6. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171 [TBL] [Abstract][Full Text] [Related]
7. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580 [TBL] [Abstract][Full Text] [Related]
9. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kistler AD; Mischak H; Poster D; Dakna M; Wüthrich RP; Serra AL Kidney Int; 2009 Jul; 76(1):89-96. PubMed ID: 19340089 [TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and outcome of autosomal dominant polycystic kidney disease in Pakistan: a single center experience. Rabbani MA; Ali SS; Murtaza G; Ahmad B; Maria Q; Siddiqui BK; Shah SM; Ahmad A J Pak Med Assoc; 2008 Jun; 58(6):305-9. PubMed ID: 18988388 [TBL] [Abstract][Full Text] [Related]
11. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
12. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease]. Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532 [TBL] [Abstract][Full Text] [Related]
13. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE; Mullen W; Wüthrich RP; Mischak H; Chapman AB PLoS One; 2013; 8(1):e53016. PubMed ID: 23326375 [TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical profile of patients with polycystic kidney disease in southern Brazil. Nunes AC; Milani V; Porsch DB; Rossato LB; Mattos CB; Roisenberg I; Barros EJ Ren Fail; 2008; 30(2):169-73. PubMed ID: 18300116 [TBL] [Abstract][Full Text] [Related]
15. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease. Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117 [TBL] [Abstract][Full Text] [Related]
16. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646 [TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease. Kim H; Koh J; Park SK; Oh KH; Kim YH; Kim Y; Ahn C; Oh YK Nephrology (Carlton); 2019 Apr; 24(4):422-429. PubMed ID: 29797773 [TBL] [Abstract][Full Text] [Related]
19. Management of ESRD in patients with autosomal dominant polycystic kidney disease. Alam A; Perrone RD Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619 [TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP; Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]